| 1 |
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding et al. · The Lancet Oncology
Open access |
2 Jun 2023 |
282 |
| 2 |
Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics
Richard S. Rogers, Nancy S. Nightlinger, Brittney Livingston et al. · mAbs
Open access |
17 Jul 2015 |
231 |
| 3 |
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich et al. · Cancer Discovery
Open access |
23 Oct 2024 |
227 |
| 4 |
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric‐Bernstam et al. · The Lancet Oncology
Open access |
15 Nov 2022 |
198 |
| 5 |
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Raffaele Colombo, Jamie R. Rich · Cancer Cell
Open access |
13 Oct 2022 |
194 |
| 6 |
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Nina E. Weisser et al. · Nature Communications
Open access |
13 Mar 2023 |
182 |
| 7 |
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J. Luke et al. · Nature Medicine
Open access |
19 Oct 2023 |
139 |
| 8 |
Improving biophysical properties of a bispecific antibody scaffold to aid developability
Thomas Spreter von Kreudenstein, Eric Escobar-Carbrera, Paula I. Lario et al. · mAbs
Open access |
24 Jul 2013 |
125 |
| 9 |
Human Subtilase SKI-1/S1P Is a Master Regulator of the HCV Lifecycle and a Potential Host Cell Target for Developing Indirect-Acting Antiviral Agents
Andrea D. Olmstead, Wolfgang Knecht, Ina Lazarov et al. · PLoS Pathogens
Open access |
5 Jan 2012 |
78 |
| 10 |
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Josep M. Tabernero, Lin Shen, Elena Elimova et al. · Future Oncology
Open access |
24 Aug 2022 |
65 |
| 11 |
Structural elements in the flexible tail of the co-chaperone p23 coordinate client binding and progression of the Hsp90 chaperone cycle
Maximilian M. Biebl, Abraham López, Alexandra Rehn et al. · Nature Communications
Open access |
5 Feb 2021 |
62 |
| 12 |
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Komal L. Jhaveri, Hyo Sook Han, Efrat Dotan et al. · Annals of Oncology
Open access |
Sep 2022 |
58 |
| 13 |
Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors
Shiekh Tanveer Ahmad, Alexandra D. Rogers, Myra J. Chen et al. · Nature Communications
Open access |
May 2019 |
54 |
| 14 |
An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer
Roland Seiler et al. · European Urology
Open access |
11 Apr 2017 |
52 |
| 15 |
Structural basis of cell wall anchoring by SLH domains in Paenibacillus alvei
Ryan J. Blackler, Arturo Lòpez-Guzmán, Fiona F. Hager‐Mair et al. · Nature Communications
Open access |
Aug 2018 |
44 |
| 16 |
LC-MS characterization and purity assessment of a prototype bispecific antibody
R. Jeremy Woods, Michael Hongwei Xie, Thomas Spreter von Kreudenstein et al. · mAbs
Open access |
Jul 2013 |
37 |
| 17 |
Defluorination Capability of l ‐2‐Haloacid Dehalogenases in the HAD‐Like Hydrolase Superfamily Correlates with Active Site Compactness
Peter W. Y. Chan, Nilmadhab Chakrabarti, Chris Ing et al. · ChemBioChem
Open access |
13 Oct 2021 |
36 |
| 18 |
Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase Inhibitor Olumacostat Glasaretil
David W. C. Hunt, Geoffrey C. Winters, Roger William Brownsey et al. · Journal of Investigative Dermatology
Open access |
Mar 2017 |
35 |
| 19 |
Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates
Mark E. Petersen et al. · Molecular Cancer Therapeutics
Open access |
13 Feb 2024 |
31 |
| 20 |
1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
Geoffrey Yuyat Ku, Elena Elimova, C.S. Denlinger et al. · Annals of Oncology
Open access |
Sep 2021 |
31 |
| 21 |
Neuroprotective Effect of Asiatic Acid in Rat Model of Focal Embolic Stroke
Ki Yong Lee, Ok‐Nam Bae, Shelley B. Weinstock et al. · Biological and Pharmaceutical Bulletin
Open access |
2014 |
30 |
| 22 |
CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis
Lewis Jonathan Dursi et al. · Cell Genomics
Open access |
Nov 2021 |
29 |
| 23 |
Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling
Katherine M. Thieltges, Dragana Avramović, Chayne L. Piscitelli et al. · Angiogenesis
Open access |
3 Mar 2018 |
23 |
| 24 |
Investigation of the Binding of a Carbohydrate‐Mimetic Peptide to its Complementary Anticarbohydrate Antibody by STD‐NMR Spectroscopy and Molecular‐Dynamics Simulations
Monica G. Szczepina, Dustin W. Bleile, Bernardine M. Pinto · Chemistry - A European Journal
|
26 Aug 2011 |
21 |
| 25 |
Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration
Mette Ø. Agerbæk et al. · International Journal of Cancer
Open access |
20 Dec 2016 |
20 |
| 26 |
Incomplete transcriptional dosage compensation of chicken and platypus sex chromosomes is balanced by post-transcriptional compensation
Nicholas C. Lister, Ashley Monique Milton, Hardip R. Patel et al. · Proceedings of the National Academy of Sciences
Open access |
29 Jul 2024 |
16 |
| 27 |
Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
F. Meric-Bernstam, D. Hanna, M. Beeram et al. · Annals of Oncology
Open access |
Oct 2019 |
16 |
| 28 |
Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering
Thomas Spreter von Kreudenstein, Paula I. Lario, Surjit B. Dixit · Methods
|
6 Nov 2013 |
15 |
| 29 |
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
Michael Z. Liao, Douglas D. Leipold, Shang‐Chiung Chen et al. · Xenobiotica
Open access |
13 May 2024 |
13 |
| 30 |
WaterLOGSY NMR Experiments in Conjunction with Molecular‐Dynamics Simulations Identify Immobilized Water Molecules That Bridge Peptide Mimic MDWNMHAA to Anticarbohydrate Antibody SYA/J6
Monica G. Szczepina, Dustin W. Bleile, Johannes Müllegger et al. · Chemistry - A European Journal
|
2 Sep 2011 |
13 |
| 31 |
Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2
Meghan M. Verstraete, Florian Heinkel, Janessa Li et al. · mAbs
Open access |
25 May 2023 |
12 |
| 32 |
Enhancing screening, brief intervention, and referral to treatment among socioeconomically disadvantaged patients: study protocol for a knowledge exchange intervention involving patients and physicians
Ginetta Salvalaggio, Kathryn A. Dong, Christine Vandenberghe et al. · BMC Health Services Research
Open access |
22 Mar 2013 |
12 |
| 33 |
Managed Architecture of Existing Code as a Practical Transition Towards MDA
Nikolai Mansurov, Djenana Campara · Lecture notes in computer science
Conference paper |
2005 |
12 |
| 34 |
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Michael G. Brant, Graham A. E. Garnett, Joy Guedia et al. · Bioorganic & Medicinal Chemistry Letters
Open access |
20 May 2023 |
11 |
| 35 |
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
Jeffrey R. Proctor, Elaina M. Gartner, Todd E. Gray et al. · Cancer Chemotherapy and Pharmacology
|
14 Sep 2022 |
11 |
| 36 |
Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
Do‐Youn Oh, Erika Paige Hamilton, Diana L. Hanna et al. · Annals of Oncology
Open access |
Nov 2019 |
11 |
| 37 |
The Crystal Structure of the Active Form of the C-Terminal Kinase Domain of Mitogen- and Stress-Activated Protein Kinase 1
Margarita L. Malakhova, Igor D’Angelo, Hong Gyum Kim et al. · Journal of Molecular Biology
Open access |
10 Apr 2010 |
10 |
| 38 |
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
Eric Escobar-Cabrera, Paula I. Lario, Jason Baardsnes et al. · Antibodies
Open access |
16 May 2017 |
9 |
| 39 |
Designed Human Serum Hyaluronidase 1 Variant, HYAL1ΔL, Exhibits Activity up to pH 5.9
Stephan Reitinger, Johannes Müllegger, Brigitte Greiderer et al. · Journal of Biological Chemistry
Open access |
29 May 2009 |
9 |
| 40 |
Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
Matthew Vogel, Raffaele Colombo, Paolo Tarantino · Journal of Clinical Oncology
|
17 Sep 2025 |
7 |
| 41 |
ZymePackNet: rotamer-sampling free graph neural network method for protein sidechain prediction
Abhishek Mukhopadhyay, Amit Kadan, Benjamin McMaster et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
6 May 2023 |
6 |
| 42 |
Incomplete transcriptional dosage compensation of vertebrate sex chromosomes is balanced by post-transcriptional compensation
Nicholas C. Lister, Ashley Monique Milton, Hardip R. Patel et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
24 Feb 2023 |
6 |
| 43 |
Facile assembly of 1,5-diazocan-2-ones via cyclization of tethered sulfonamides to cyclopropenes
Jonathon P. Matheny, Pavel M. Yamanushkin, Peter A. Petillo et al. · RSC Advances
Open access |
2020 |
6 |
| 44 |
ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity
Gordon Ng, Thomas Spreter, Rupert Hugo Davies et al. · Blood
|
2 Dec 2016 |
6 |
| 45 |
Computer-assisted design of industrial enzymes The resurgence of rational design and in silico mutagenesis
John Vieceli, Johannes Müllegger, Ali Mostafa Tehrani · Industrial Biotechnology
|
Dec 2006 |
6 |
| 46 |
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Mark E. Petersen, Michael G. Brant, Manuel Lasalle et al. · Journal of Medicinal Chemistry
|
12 Jun 2023 |
5 |
| 47 |
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics
Florian Heinkel, Meghan M. Verstraete, Siran Cao et al. · mAbs
Open access |
7 Nov 2022 |
5 |
| 48 |
AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design
Mário Sanches, Igor D’Angelo, Maria Isabel Jaramillo et al. · mAbs
Open access |
2020 |
5 |
| 49 |
Ubisol-AquaTM: Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model
Catherine Louise Cherry, Masqura Mobarok, Steve L Wesselingh et al. · Current HIV Research
|
Apr 2010 |
5 |
| 50 |
Lymphocyte-derived cholinergic circuits modulate germinal center output and B cell activation
Duygu Nechanitzky, Logan K. Smith, Robert Nechanitzky et al. · Nature Immunology
|
24 Feb 2026 |
4 |